SetPoint System
SetPoint Medical · Decision date Jan 16, 2026
What did the FDA approve?
FDA records P240039/S001 as a supplement to PMA P240039, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated Jan 16, 2026.
FDA approval order statement
The SetPoint System is indicated for use in the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response, loss of response, or intolerance to one or more biological or targeted synthetic disease modifying antirheumatic drugs (b/tsDMARDs).
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track No User Fee
- Clinical specialty
- Neurology
- Decision date
- Jan 16, 2026
- FDA change category
- Postapproval Study Protocol
Regulatory record facts
- Identifier
- P240039/S001
- Regulatory pathway
- PMA supplement
- Applicant
- SetPoint Medical
- Product code
- SFJ
- Decision code
- APPR
- Decision date
- Jan 16, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Vagus nerve stimulator for rheumatoid arthritis.
- Applicant
- SetPoint Medical
- Product code
- SFJ
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P240039. Subsequent supplements may change the device or its indications.
FDA decision timeline
P240039 · Original PMA
SetPoint System
P240039/S001 received
Application receipt date recorded by FDA.
P240039/S001 · FDA decision
Normal 180 Day Track No User Fee
P240039/S002 · Related supplement
SetPoint System
P240039/S003 · Related supplement
Charger SetPoint System
P240039/S004 · Related supplement
SetPoint System
Timeline entries are records held by MedtechLedger for P240039. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P240039
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
SetPoint SystemP240039 | SetPoint Medical | PMA approval | Jul 30, 2025 | FDA |
SetPoint SystemP240039/S002 | SetPoint Medical | PMA supplement | Feb 18, 2026 | FDA |
Charger SetPoint SystemP240039/S003 | SetPoint Medical | PMA supplement | Oct 16, 2026 | FDA |
SetPoint SystemP240039/S004 | SetPoint Medical | PMA supplement | Oct 29, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
SetPoint Medical
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 25101 Rye Canyon Loop, Valencia, CA, 91355
Sources and methodology
- Original FDA record: P240039/S001
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

